Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
Article in Translational Lung Cancer Research (April 2024)
The most recent citing publications are shown below. View all 33 publications that cite this research output on Dimensions.
Article in Translational Lung Cancer Research (April 2024)
Article in PeerJ (March 2024)
Article in Translational Lung Cancer Research (September 2023)